# NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines

> **NCT00777803** · PHASE3 · COMPLETED · sponsor: **Merz Pharmaceuticals GmbH** · enrollment: 381 (actual)

## Conditions studied

- Glabellar Frown Lines

## Interventions

- **DRUG:** NT 201 (IncobotulinumtoxinA (Xeomin®/Bocouture®))
- **DRUG:** OnabotulinumtoxinA (Vistabel®)

## Key facts

- **NCT ID:** NCT00777803
- **Lead sponsor:** Merz Pharmaceuticals GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-04
- **Final completion:** 2009-05
- **Target enrollment:** 381 (ACTUAL)
- **Last updated:** 2012-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00777803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00777803, "NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00777803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*